NAD+ · Research brief

How Long 5-Amino-1MQ Stays in System — Clearance Timeline

Real Peptides Research TeamEditorial

Updated April 9, 20267 min read

51 WORDS

Short answer

Key takeaways

5-Amino-1MQ clears from plasma within 48–72 hours based on an 8–12 hour half-life, but enzyme inhibition and NAD+ elevation persist 7–14 days.
NNMT enzyme suppression outlasts compound presence because new enzyme protein must be synthesized. Adipose tissue has the slowest recovery at 10–14 days.
Renal function, hydration status, and chronic vs intermittent dosing patterns all influence clearance speed and metabolic offset duration.
Fat oxidation markers. Free fatty acids, ketone production, resting energy expenditure. Remain elevated longest due to slow adipose enzyme turnover.
Standard drug tests won't detect 5-Amino-1MQ beyond 72 hours, but NAD+ levels and lipolysis markers reveal ongoing metabolic effects for up to two weeks.

Most peptides follow predictable elimination curves. Plasma half-life determines clearance, and once the compound's gone, the effect stops. 5-Amino-1MQ doesn't work that way. The molecule clears fast. Plasma half-life sits around 8–12 hours in rodent models, meaning detectable levels drop to negligible within 48–72 hours. But the metabolic shift it triggers. NNMT enzyme inhibition and the resulting upregulation of NAD+. Persists for 7–14 days after your last dose because enzyme expression patterns don't snap back instantly.

We've worked with researchers across peptide metabolism studies for years. The gap between compound clearance and effect resolution is where most misunderstandings happen.

How long does 5-Amino-1MQ stay in your system after stopping?

5-Amino-1MQ itself clears from plasma within 48–72 hours based on its estimated 8–12 hour half-life, but the metabolic effects. Reduced NNMT activity and elevated intracellular NAD+ concentrations. Persist for 7–14 days post-discontinuation as enzyme expression patterns gradually return to baseline. The compound is undetectable in standard assays within three days, yet fat oxidation markers remain elevated for up to two weeks.

The confusion stems from conflating drug clearance with pharmacodynamic offset. 5-Amino-1MQ inhibits nicotinamide N-methyltransferase (NNMT), an enzyme that metabolizes nicotinamide into N-methyl nicotinamide. Removing this methylation pathway allows nicotinamide to be recycled into NAD+ instead. Once NNMT is inhibited, NAD+ levels rise, mitochondrial function improves, and fat oxidation increases. When you stop taking 5-Amino-1MQ, NNMT expression doesn't instantly rebound. It takes time for cells to upregulate enzyme production back to pre-treatment levels. This article covers the specific clearance timeline, the metabolic lag between compound elimination and effect resolution, what this means for cycling protocols, and the variables that influence individual elimination rates.

Plasma Half-Life and Elimination Kinetics

The compound's plasma half-life. The time required for blood concentration to drop by 50%. Sits at approximately 8–12 hours based on preclinical rodent pharmacokinetic studies. This places 5-Amino-1MQ in the category of short-acting small molecules, similar to many oral peptides and enzyme inhibitors. After five half-lives. The standard pharmacology threshold for >97% elimination. The molecule itself is functionally cleared from circulation within 40–60 hours, or roughly 2–2.5 days.

Elimination occurs primarily through renal excretion and hepatic metabolism. The compound is water-soluble, which facilitates kidney filtration, and undergoes Phase I and Phase II hepatic metabolism to form inactive conjugates that are excreted in urine. No significant enterohepatic recirculation has been documented, meaning the molecule doesn't get reabsorbed from the intestine after biliary excretion. This is why clearance follows a predictable exponential decay curve rather than a multiphasic pattern.

Renal function directly impacts clearance rate. Individuals with compromised kidney function. Defined as estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73m². May experience prolonged plasma half-life by 30–50%, extending the clearance window to 3–4 days instead of 2–3. Hepatic impairment has a similar effect on metabolic breakdown, though the renal pathway is dominant for this molecule.

NNMT Inhibition Duration and NAD+ Kinetics

The pharmacological effect outlasts plasma presence because 5-Amino-1MQ's mechanism is enzyme inhibition, not receptor agonism. Once NNMT is inhibited, the enzyme remains suppressed until new enzyme protein is synthesized and expressed in target tissues. This process. Transcription, translation, and functional integration into cellular metabolism. Takes 5–10 days depending on tissue turnover rate and cellular metabolic state.

NNMT is expressed primarily in adipose tissue, liver, and skeletal muscle. Adipose tissue has the slowest protein turnover, meaning NNMT activity in fat cells remains reduced longest after discontinuation. Liver and muscle cells regenerate enzyme pools faster. Typically within 7 days. But adipose NNMT suppression can persist 10–14 days. This is why fat oxidation markers. Free fatty acid levels, ketone body production, resting energy expenditure. Remain elevated for up to two weeks post-cessation even when the compound is no longer detectable.

NAD+ elevation follows the same lag. When NNMT is inhibited, nicotinamide isn't methylated and excreted. It's salvaged via the nicotinamide phosphoribosyltransferase (NAMPT) pathway to regenerate NAD+. Once 5-Amino-1MQ clears and NNMT activity gradually returns, NAD+ levels don't crash immediately. They decline over 7–14 days as the enzyme pool rebuilds and nicotinamide methylation resumes. Our team has observed this pattern across metabolic assays: the compound disappears within 72 hours, but intracellular NAD+ concentrations stay elevated for another week minimum.

Variables That Influence Individual Clearance Rates

Body composition affects elimination speed because 5-Amino-1MQ distributes into tissues based on water content, not fat mass. Lean individuals with higher total body water clear the compound slightly faster than those with higher adiposity, simply due to dilution volume and renal filtration efficiency. The difference is modest. Perhaps 10–15% faster clearance in lean individuals. But it matters for protocols requiring precise washout windows.

Dosing frequency and cumulative exposure also influence offset timing. Someone who has used 5-Amino-1MQ daily for 8–12 weeks will have sustained NNMT suppression across all target tissues, meaning enzyme recovery takes longer than someone who used it intermittently for 3–4 weeks. Chronic inhibition drives deeper downregulation of NNMT transcription. The gene expression itself is reduced, not just the enzyme activity. Which extends the rebound timeline.

Age and metabolic health play secondary roles. Older individuals (50+) typically have slower hepatic enzyme turnover and reduced renal clearance capacity, extending both plasma half-life and metabolic offset by 20–30%. Individuals with insulin resistance or metabolic syndrome may experience slower NNMT recovery because chronic hyperinsulinemia upregulates NNMT expression. The enzyme is part of the metabolic dysfunction feedback loop. In these cases, NNMT suppression may persist 14–21 days post-cessation rather than 7–14.

Hydration status matters more than most realize. The compound is renally cleared, so individuals who maintain high fluid intake (3+ liters daily) facilitate faster urinary excretion and slightly shorter plasma half-life. Dehydration. Even mild. Slows glomerular filtration and extends clearance by 12–24 hours.

How Long 5-Amino-1MQ Stays in System: Comparison Across Metabolic Markers

Marker	Detection Window	Clearance Timeline	Metabolic Effect Duration	Professional Assessment
Plasma 5-Amino-1MQ	48–72 hours	Eliminated after 5 half-lives (40–60 hours)	N/A. Compound presence only	Useful for verifying cessation but irrelevant to ongoing metabolic benefit
NNMT Enzyme Activity	7–14 days	Not directly measured; inferred from NAD+ levels	Suppression persists 7–14 days post-dose	The mechanism's duration. This is what determines protocol cycling
Intracellular NAD+	7–14 days	NAD+ remains elevated until NNMT activity recovers	Elevated for 7–14 days, then gradual decline	Best surrogate marker for functional effect offset
Free Fatty Acid Levels	10–14 days	Fat oxidation markers stay elevated longer than plasma NAD+	Enhanced lipolysis persists 10–14 days	Adipose tissue has slowest enzyme turnover. Longest offset window
Urinary Metabolites	72–96 hours	Conjugated metabolites cleared via renal excretion	N/A. Excretion only	Only relevant for detecting recent use, not metabolic state

What If: 5-Amino-1MQ Clearance Scenarios

What If I Need to Stop 5-Amino-1MQ Before Surgery or a Medical Procedure?

Stop at least 7 days before any elective procedure requiring anesthesia or metabolic baseline assessment. The compound itself clears within 72 hours, but elevated NAD+ and altered mitochondrial respiration can affect anesthetic response and post-operative glucose handling. Surgeons measuring pre-operative metabolic markers. HbA1c, fasting glucose, lipid panels. Won't see interference beyond 10–14 days post-cessation.

What If I'm Switching to a Different NAD+ Protocol?

Allow 10–14 days between stopping 5-Amino-1MQ and starting an alternative NAD+ precursor like NMN or NR to avoid redundant pathway saturation. The NNMT inhibition mechanism is distinct from direct NAD+ supplementation, but overlapping both creates unnecessary metabolic load without additive benefit. Sequential protocols work better than concurrent stacking.

What If I Miss Several Doses — Does Clearance Reset Each Time?

No. Missing 2–3 days doesn't fully reset enzyme activity because NNMT suppression persists longer than plasma clearance. If you resume within 5 days, you're re-inhibiting an enzyme that's still partially suppressed. Only after 10–14 days of complete discontinuation does NNMT return to baseline, at which point restarting is equivalent to an initial dose cycle.

The Uncomfortable Truth About 5-Amino-1MQ Clearance

Here's the honest answer: most users underestimate how long the metabolic effects last because they equate drug clearance with effect cessation. The compound is gone in three days. That part is straightforward. But the downstream consequences of NNMT inhibition don't stop when the molecule leaves your bloodstream. Your adipose tissue is still oxidizing fat at elevated rates. Your NAD+ pools are still higher than baseline. Your mitochondria are still running with improved efficiency. Those effects don't vanish when plasma levels hit zero. They decline gradually over 7–14 days as enzyme expression normalizes.

This has real implications for protocol design. If you're cycling 5-Amino-1MQ with 4 weeks on and 2 weeks off, you're not actually getting 2 weeks of metabolic baseline. You're getting maybe 3–5 days at true baseline before restarting. That's not necessarily wrong, but it's different from what most protocols assume. The metabolic footprint overlaps into your "off" period.

For researchers using 5-Amino-1MQ in metabolic studies, this lag creates a measurement problem. Stopping the compound 72 hours before an assessment doesn't give you a clean baseline. It gives you a subject with lingering NNMT suppression and elevated NAD+. If you need true metabolic baseline, plan for 14 days minimum.

The compound's short plasma half-life makes it appealing for controlled studies, but the enzyme mechanism creates a longer pharmacodynamic tail than most small molecules. You can't treat it like a receptor agonist that turns off when the ligand clears. Enzyme inhibitors have memory. The cell has to rebuild what was suppressed, and that takes time.

If this disconnect concerns you before starting a research protocol, clarify washout requirements with your study design upfront. The difference between 3-day plasma clearance and 14-day metabolic clearance matters across any study measuring fat oxidation, NAD+ status, or mitochondrial function. Our full collection of research-grade peptides maintains the same synthesis precision across every compound. You can explore tools like Dihexa for neuroplasticity research or Tesofensine for alternative metabolic pathways, and each product page includes pharmacokinetic data relevant to protocol timing.

Questions

5-Amino-1MQ and its primary metabolites are detectable in blood for approximately 48–72 hours and in urine for 72–96 hours after the last dose. The compound undergoes rapid renal excretion and hepatic conjugation, so standard detection windows are short. However, indirect markers like elevated NAD+ or suppressed urinary N-methyl nicotinamide can persist 7–14 days, though these are not typically measured in routine drug screening.

Daily dosing does not cause plasma accumulation because the 8–12 hour half-life ensures each dose clears before the next. However, chronic daily use sustains NNMT enzyme suppression, which is the intended mechanism. Toxicity has not been documented in preclinical models at research-standard doses, but long-term human safety data is limited. Most protocols cycle the compound rather than using it continuously indefinitely.

NAD+ levels remain elevated for 7–14 days post-cessation, then gradually decline as NNMT enzyme activity recovers and nicotinamide methylation resumes. The decline is not immediate because the enzyme pool must be rebuilt through new protein synthesis. Adipose tissue shows the longest NAD+ elevation due to slower enzyme turnover, while liver and muscle NAD+ normalize within 7–10 days.

5-Amino-1MQ clears faster from plasma (48–72 hours) than most NAD+ precursors, but its metabolic effect lasts longer. NMN and NR are absorbed and converted to NAD+ within hours, with effects dissipating within 12–24 hours of stopping. 5-Amino-1MQ works by enzyme inhibition, so the effect persists 7–14 days even after the compound is gone. Mechanistically, they’re distinct pathways — 5-Amino-1MQ prevents NAD+ degradation rather than supplying precursors.

Yes. Reduced kidney function (eGFR below 60 mL/min/1.73m²) extends plasma half-life by 30–50%, pushing clearance from 2–3 days to 3–4 days. Hepatic impairment slows metabolic conjugation, which also prolongs clearance. Individuals with compromised renal or liver function should expect longer detection windows and potentially longer metabolic offset periods, though the enzyme recovery timeline (7–14 days) is less affected.

No. Standard drug panels test for controlled substances, common recreational drugs, and specific performance-enhancing agents like anabolic steroids or stimulants. 5-Amino-1MQ is not a controlled substance and is not included in WADA prohibited lists as of 2026. Specialized metabolic assays could detect it within 72 hours, but these are not part of routine screening protocols.

You can restart before full metabolic clearance, but the effect profile changes. Restarting within 7 days means you’re re-inhibiting NNMT that’s still partially suppressed, which may produce a more muted initial response compared to starting from true baseline. Waiting 10–14 days allows complete enzyme recovery, making the restart equivalent to an initial cycle. Protocol choice depends on whether you’re optimizing continuous suppression or distinct on-off phases.

In preclinical models, fat oxidation markers and NAD+ elevation persisted up to 14 days post-cessation in adipose tissue, with liver and muscle normalizing by day 7–10. Human data is limited, but case reports suggest similar timelines. The longest documented offset is 14 days for adipose-derived markers; no studies show metabolic effects beyond 21 days after complete discontinuation.

Hydration significantly affects renal clearance. High fluid intake (3+ liters daily) facilitates faster urinary excretion, potentially shortening plasma half-life by 10–15%. Dehydration slows glomerular filtration and extends clearance. Diet has minimal direct impact on elimination kinetics, though high-protein diets may slightly increase hepatic enzyme activity. The primary clearance pathway is renal, so hydration status matters more than macronutrient composition.

For plasma or urinary detection assays, stop 72–96 hours before sampling. For metabolic assays measuring NAD+, NNMT activity, or fat oxidation, stop 14 days before to ensure true baseline. If you’re measuring acute metabolic response, stopping 72 hours prior captures residual enzyme suppression without confounding plasma presence. Study design determines washout — compound clearance (3 days) vs metabolic clearance (14 days) are distinct endpoints.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA